Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

117
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
117
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

666
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

1.9K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
1.9K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.0K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.0K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.0K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term systolic blood pressure time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.

American journal of hypertension·2026
Same author

Association between eGFR and Disability-Free Survival in Older Adults Varies by Physical Function.

Kidney360·2026
Same author

The Surgical Clerkship Guide: A Practical Framework for Confidence and Competence.

Cureus·2026
Same author

Editorial Comment.

The Journal of urology·2026
Same author

Evaluating Long-Term Outcomes Across eGFR Equations in Older Adults.

Kidney international reports·2026
Same author

Male Parameatal Urethral Cyst: A Report of Two Cases and Literature Review.

Case reports in urology·2026

Related Experiment Video

Updated: Nov 15, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

958

Drug Interactions with Antihypertensives.

Michelle A Fravel1, Michael Ernst2

  • 1University of Iowa College of Pharmacy, 167 CB, 180 S. Grand Ave, Iowa City, IA, 52242, USA. michelle-fravel@uiowa.edu.

Current Hypertension Reports
|March 5, 2021
PubMed
Summary

Hypertension drug interactions are common due to polypharmacy. Clinicians must understand pharmacokinetic and pharmacodynamic interactions to manage risks and personalize antihypertensive therapy.

Keywords:
Antihypertensive agentsDrug-drug interactionsPharmacodynamic drug interactionsPharmacokinetic drug interactions

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.7K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.2K

Related Experiment Videos

Last Updated: Nov 15, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

958
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.7K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.2K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Pharmacy

Background:

  • Hypertension affects over 1.13 billion people globally.
  • Hypertension management often involves multiple drugs and comorbidities, increasing polypharmacy.
  • Polypharmacy in hypertensive patients significantly elevates the risk of drug interactions.

Purpose of the Study:

  • To review literature on drug interactions involving antihypertensive medications.
  • To aid clinicians in identifying and mitigating drug interaction risks.
  • To provide guidance for safer antihypertensive prescribing.

Main Methods:

  • Literature review summarizing pharmacokinetic and pharmacodynamic interactions.
  • Analysis of drug interactions involving specific antihypertensive classes.
  • Discussion of emerging concepts like drug-induced phenoconversion.

Main Results:

  • Calcium channel blockers (diltiazem, verapamil) are potent CYP3A4 inhibitors, causing many antihypertensive drug interactions.
  • Other antihypertensive classes also exhibit pharmacokinetic interactions, though less frequently.
  • Pharmacodynamic interactions can alter blood pressure control and adverse effect profiles.

Conclusions:

  • Understanding drug-drug interactions is crucial for hypertensive patients with comorbidities and polypharmacy.
  • Emerging knowledge on phenoconversion impacts personalized medicine approaches.
  • Further research into pharmacokinetic interactions and pharmacogenomics is vital for advancing personalized antihypertensive therapy.